Advances in the development of new biologics in inflammatory bowel disease

RDF 

 
This item is provided by the institution :
Hellenic Gastroenterologiki Company
Repository :
Annals of Gastroenterology
see item page
in the web site of the repository *
share



Semantic enrichment/homogenization by EKT
Advances in the development of new biologics in inflammatory bowel disease (EN)

Ungar, Bella
Kopylov, Uri

Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infl iximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.Keywords Infl ammatory bowel disease, Crohn’s disease, ulcerative colitis, therapy, biologicsAnn Gastroenterol 2016; 29 (3): 243-248 (EN)

Ελληνική Γαστροεντερολογική Εταιρία (EL)
Hellenic Gastroenterologiki Company (EN)

2016-06-29


Annals of Gastroenterology (EN)

Annals of Gastroenterology; Volume 29, No 3 (2016); 243 (EN)



*Institutions are responsible for keeping their URLs functional (digital file, item page in repository site)